Teva Settles Patent Litigation With Astrazeneca, Enters Into License Agreement
June 23, 2016 at 11:57 AM EDT
The settlement allows Teva to commercialize its generic version of BYETTA in the U.S. beginning October 15, 2017 or earlier under certain circumstances.
